Cargando…
Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM)
Fundamental measurement is the basis for a rational assessment of patient reported outcome (PRO) value claims; both as response to therapy and the submission of credible and evaluable value claims to formulary committees and other health system decision makers. It is important to emphasize the impor...
Autor principal: | Langley, Paul C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
University of Minnesota Libraries Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836750/ https://www.ncbi.nlm.nih.gov/pubmed/36654699 http://dx.doi.org/10.24926/iip.v13i2.4861 |
Ejemplares similares
-
Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions
por: Dong, Tiffany, et al.
Publicado: (2023) -
Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy
por: Scholtz, Smita, et al.
Publicado: (2023) -
The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients
por: DeVries, J Hans, et al.
Publicado: (2023) -
The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review
por: Edelberg, Jay M., et al.
Publicado: (2022) -
Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial
por: Tian, Zhuang, et al.
Publicado: (2023)